-
881
-
882
Synergistic strategies for glioblastoma treatment: CRISPR-based multigene editing combined with immune checkpoint blockade
Published 2025-02-01“…Abstract Glioblastoma (GBM) is a primary brain tumor known for its high levels of aggressiveness and resistance to current treatments such as radiotherapy and chemotherapy. As a result, there is a pressing need for innovative therapeutic approaches to combat GBM. …”
Get full text
Article -
883
Ionizing radiation and photodynamic therapy lead to multimodal tumor cell death, synergistic cytotoxicity and immune cell invasion in human bladder cancer organoids
Published 2025-02-01“…Background: Photodynamic therapy (PDT) and radiotherapy using ionizing radiation (IR) are promising options for organ-preserving treatment of bladder cancer (BCa). …”
Get full text
Article -
884
A high-valence bismuth(V) nanoplatform triggers cancer cell death and anti-tumor immune responses with exogenous excitation-free endogenous H2O2- and O2-independent ROS generation
Published 2025-01-01“…NaBiVO3-PEG intravenously administered can efficiently accumulate at the tumor site for further real-time computed tomography monitoring, immunotherapy, or alternative synergistic immune-radiotherapy. Overall, this work offers a nanomedicine based on high-valence bismuth(V) nanoplatform and underscores its great potential for cancer immunotherapy.…”
Get full text
Article -
885
Cyclooxygenase-2/prostaglandin E2 inhibition remodulated photodynamic therapy-associated immunosuppression for enhanced cancer immunotherapy
Published 2025-04-01“…This study sets an intriguing example for overcoming the COX-2/PGE2 pathway-exacerbated immunosuppression alongside immune activation, thus enhancing synergistic cancer immunotherapy potentiated by various ROS-producing therapies (e.g., PDT and radiotherapy) and chemotherapy.…”
Get full text
Article -
886
Highlights of Thirty-Year Experience of CO2 Laser Use at the Florence (Italy) Department of Dermatology
Published 2012-01-01“…Tumor recurrence is minor compared with radiotherapy or surgery. This method is a valid alternative to surgery and/or diathermocoagulation for microsurgery of soft tissues. …”
Get full text
Article -
887
Breast cancer patients with a pre-existing mental illness are less likely to receive guideline-recommended cancer treatment: A systematic review and meta-analysis
Published 2025-02-01“…Meta-analysis revealed that patients with mental illnesses were significantly less likely to receive guideline-recommended treatments (OR = 0.78, 95 % CI 0.72–0.83, N = 5), chemotherapy (OR = 0.56, 95 % CI 0.34–0.78, N = 6), or radiotherapy (OR = 0.79, 95 % CI 0.66–0.93, N = 5). They were also significantly more likely to undergo mastectomy instead of breast-conserving surgery (OR = 1.38, 95 % CI 1.24–1.52, N = 4). …”
Get full text
Article -
888
Functional outcomes in early (T1/T2) supraglottic cancer: a systematic review
Published 2018-12-01“…Abstract Objectives Organ preserving surgery (OPS) and radiotherapy (RT) are both accepted treatment options for early stage supraglottic cancer (SGC). …”
Get full text
Article -
889
Comparison of prophylactic topical application of Cryptomphalus aspersa secretion versus betamethasone for telecobalt radiation-induced skin reactions in locally advanced head and...
Published 2025-02-01“…Radiation-induced acute skin reaction is of major concern during and after definitive course of radiotherapy. Prevention and treatment of these reactions play an important role in the completion of the prescribed course of EBRT within stipulated time period while maintaining the quality of life. …”
Get full text
Article -
890
Patterns of regional recurrence in papillary thyroid cancer patients with lateral neck metastases undergoing neck dissection
Published 2017-05-01“…Significant predictors of regional failure were the total number of suspicious nodes on preoperative imaging (p = 0.029), largest positive node on initial neck dissection (p < 0.01), and whether patients received adjuvant radiotherapy (p = 0.028). The 5-year ipsilateral regional recurrence rate was 8 and 9% with selective and comprehensive dissection, respectively (p = 0.89). …”
Get full text
Article -
891
Clinicopathological characteristics and survival outcomes of women aged ≤45 and >45 years with endometrial adenocarcinoma in tertiary referral hospital: a 21-year cohort study
Published 2025-01-01“…Objective This study aimed to compare clinicopathological characteristics and oncological outcomes in patients with endometrial cancer aged ≤45 and >45 years, with a focus on identifying distinct traits and prognostic factors in younger patients.Design A retrospective cohort study.Setting The study was conducted at King Chulalongkorn Memorial Hospital, Bangkok, Thailand, with a restricted study population from 1996 to 2016.Participants A total of 1114 patients diagnosed with endometrial cancer and underwent surgery were strictly selected, excluding those who had received primary radiotherapy or had uterine sarcoma. Among the population, 188 patients (16.9%) were ≤45 years old and 926 patients (83.1%) were >45 years old.Outcome measures The primary outcome measures were disease-free survival (DFS) and overall survival (OS) at 5, 10 and 15 years, with an analysis of survival rates based on patient age groups and prognostic factors.Results Younger patients (≤45 years) displayed significantly higher rates of obesity, nulliparity and polycystic ovary syndrome (PCOS), as well as favourable pathological characteristics such as well-differentiated tumours and lower rates of myometrial invasion. …”
Get full text
Article -
892
Prognostic Impact of miR-224 and RAS Mutations in Medullary Thyroid Carcinoma
Published 2017-01-01Get full text
Article -
893
Personalized treatment strategies for breast adenoid cystic carcinoma: A machine learning approach
Published 2025-02-01“…The 5-year overall survival (OS) rates were highest for surgery + radiotherapy (RT) (94.9 %) and lowest for surgery + chemotherapy (CTX) + RT (80.1 %). …”
Get full text
Article -
894
Intricacies of human–AI interaction in dynamic decision-making for precision oncology
Published 2025-01-01“…To investigate such collaborative decision-making process, we conducted a Human–AI interaction study on response-adaptive radiotherapy for non-small cell lung cancer and hepatocellular carcinoma. …”
Get full text
Article -
895
Prognostic Role of Monocytic Myeloid-Derived Suppressor Cells in Advanced Non-Small-Cell Lung Cancer: Relation to Different Hematologic Indices
Published 2021-01-01“…We recruited 40 cases of advanced NSCLC, stages III and IV, aged>18–<70 years old, and eligible to receive chemotherapy with or without radiotherapy, along with 20 healthy controls of comparable age and sex; after diagnosis and staging of patients, blood samples were collected for flow cytometric detection of Mo-MDSCs. …”
Get full text
Article -
896
Global research trends on gastrointestinal cancer and mental health (2004–2024): a bibliographic study
Published 2025-01-01Get full text
Article -
897
Outcomes of oncologic arthroplasty in children and adolescents with malignant limb tumors: a systematic review
Published 2024-12-01“…However, the development and refinement of chemotherapy and radiotherapy protocols, along with advances in surgical techniques and implants, have significantly altered the treatment landscape for these patients. …”
Get full text
Article -
898
Computational insights into Sitahe (Leuconotis eugenifolia) bioactive compounds: A promising approach for radioprotection through p53 inhibition
Published 2025-01-01“…The radioprotective potential of Sitahe (Leuconotis eugenifolia) phytochemicals in cancer radiotherapy remains largely unexplored. In this study, in silico docking simulations were conducted to systematically assess the ability of key phytochemicals from Sitahe to modulate p53 activity, a critical gene in DNA repair and cancer therapy. …”
Get full text
Article -
899
Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome– paving the path towards precision medicine: a case report
Published 2025-01-01“…Due to impaired DNA damage repair, conventional cytotoxic therapies or radiotherapy should be avoided whenever feasible to mitigate the high incidence of treatment-related secondary malignancies in these patients. …”
Get full text
Article -
900
CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer
Published 2025-02-01“…Preclinical studies indicate that CDK4/6i may collaborate by influencing DNA damage repair pathways during radiotherapy. Since PARP1 expression was also significantly upregulated in NSCLC, we analyzed the efficacy of combining PARP1 and CDK4/6 inhibition in NSCLC models. …”
Get full text
Article